Skip to main content
SpringerLink
Log in

Scleroderma lung disease: a common phenomenon in a rare disease

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Harris Jr ED. Systemic sclerosis (scleroderma). In: Wyngaarden JB, Smith LH, editors. Cecil textbook of medicine. 17th ed. Philadelphia: W.B. Saunders Company, 1985: 1932–36

    Google Scholar 

  2. Nuki G. Diseases of connective tissues, joints and bones. In: Edwards CRW, Bouchier IAD, Haslett C, editors. Davidson’s principles and practice of medicine. 17th ed. Edinburgh: Churchill Livingstone, 1995: 863–940

    Google Scholar 

  3. Brown DA, Breit SN. Scleroderma lung disease: appropriate management. BioDrugs 1997 Sep; 8(3): 185–92

    Article  PubMed  CAS  Google Scholar 

  4. Williamson DJ. Management of scleroderma: a multidisciplinary approach. Current Therapeutics 1996 Sep; 37: 53–7

    Google Scholar 

  5. Crompton GK, Haslett C. Diseases of the respiratory system. In: Edwards CRW, Bouchier IAD, Haslett C, editors. Davidson’s principles and practice of medicine. 17th ed. Edinburgh: Churchill Livingstone, 1995: 313–404

    Google Scholar 

  6. D’Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46(3): 428–40

    Article  PubMed  Google Scholar 

  7. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: enhanced production and profibrotic action. Arthritis Rheum 1991; 34(8): 978–83

    Article  PubMed  CAS  Google Scholar 

  8. Giaid AAU, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341(8860): 1550–4

    Article  PubMed  CAS  Google Scholar 

  9. Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990; 21(5): 467–74

    Article  PubMed  CAS  Google Scholar 

  10. Wallman L, Penny R, Williamson D. Pulmonary vascular aspects of systemic sclerosis. Aust NZ J Med 1996: 26(2): 150–3

    Article  CAS  Google Scholar 

  11. Steen VD, Graham G, Conte C, et al. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35(7): 765–70

    Article  PubMed  CAS  Google Scholar 

  12. Cairns D, Shelley L, Burke W, et al. The differing patterns of interstitial lung involvement in connective tissue diseases. J Rheumatol 1992; 19(7): 1089–95

    PubMed  CAS  Google Scholar 

  13. Steen VD, Lanz Jr JK, Conte C, et al. Therapy for severe interstitial lung disease in systemic sclerosis: a retrospective study. Arthritis Rheum 1994; 37(9): 1290–6

    Article  PubMed  CAS  Google Scholar 

  14. Silver R, Miller K, Kinsella M. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88: 470–6

    Article  PubMed  CAS  Google Scholar 

  15. Steen V. Treatment of systemic sclerosis. Curr Opin Rheumatol 1991; 3: 979–85

    Article  PubMed  CAS  Google Scholar 

  16. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124(9): 820–4

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scleroderma lung disease: a common phenomenon in a rare disease. Drugs Ther. Perspect 11, 9–11 (1998). https://doi.org/10.2165/00042310-199811100-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199811100-00003

Keywords

Search

Navigation